REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio hit with another clinical hold for Hunter syndrome gene therapy

Regenxbio's RGX-121 Hunter syndrome gene therapy faces second clinical hold after spinal lumps found in 5 CAMPSIITE trial patients, sending $RGNX shares down 23%.